Key statistics
As of last trade, Idorsia Ltd (IDIA:SWX) traded at 0.7425, 21.42% above the 52 week low of 0.6115 set on Nov 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.725 |
---|---|
High | 0.79 |
Low | 0.72 |
Bid | 0.7405 |
Offer | 0.7445 |
Previous close | 0.7225 |
Average volume | 1.25m |
---|---|
Shares outstanding | 189.33m |
Free float | 121.09m |
P/E (TTM) | -- |
Market cap | 136.79m CHF |
EPS (TTM) | -1.68 CHF |
Data delayed at least 15 minutes, as of Nov 21 2024 14:32 GMT.
More ▼
- Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions
- Idorsia announces financial results for the first nine months of 2024
- New data on aprocitentan to be presented at the ASN Kidney Week 2024
- Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024
- New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024
- Amended terms of Idorsia’s 2024 convertible bonds become effective
- Idorsia announces financial results for the first half 2024
- Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call
- Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension
- Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds
More ▼